Loading clinical trials...
Loading clinical trials...
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, COMPARING IVERMECTIN CREAM 1% (ZYDUS WORLDWIDE DMCC) TO SOOLANTRA® (GALDERMA LABORATORIES, L.P.) AND BOTH ACTIVE TREATMENTS TO A PLACEBO CONTROL IN THE TREATMENT OF MODERATE TO SEVERE FACIAL ROSACEA
Conditions
Interventions
Soolantra® Ivermectin cream 1%
Ivermectin cream 1%
+1 more
Locations
11
United States
Zydus Worldwide DMCC
Brandon, Florida, United States
Zydus Worldwide DMCC
Fort Lauderdale, Florida, United States
Zydus Worldwide DMCC
Miami, Florida, United States
Zydus Worldwide DMCC
Miramar, Florida, United States
Zydus Worldwide DMCC
Tampa, Florida, United States
Zydus Worldwide DMCC
Saginaw, Michigan, United States
Start Date
October 17, 2019
Primary Completion Date
August 4, 2020
Completion Date
August 4, 2020
Last Updated
October 14, 2020
Lead Sponsor
Zydus Worldwide DMCC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions